Incidence of hypoxia during intravitreal ranibizumab injections for retinopathy of prematurity under topical anesthesia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This retrospective multicenter observational study examined premature infants treated with intravitreal ranibizumab for treatment-requiring ROP between July 2020 and June 2026 at Qassim University Medical City. During each bedside procedure, continuous pulse oximetry was recorded to classify hypoxia as mild, moderate, or severe. The analysis included demographic, maternal, perinatal, ophthalmic, and treatment-related variables to describe incidence and severity and to identify potential risk factors. The goal is to address an evidence gap regarding intraprocedural hypoxia in this setting across multiple hospitals in the Al Qassim region of Saudi Arabia.

Why it matters

Who can join: the full rules

Inclusion criteria

* Premature infants with treatment-requiring ROP.
* Treatment with intravitreal ranibizumab.
* Complete procedural monitoring records, including continuous pulse oximetry.
* Availability of follow-up data after treatment. Exclusion criteria

Infants were excluded if they had:

* Incomplete procedural or follow-up data.
* Major congenital anomalies affecting cardiorespiratory function.
* Bronchopulmonary dysplasia.
* Intraventricular hemorrhage.
* Patent ductus arteriosus.
* Respiratory distress syndrome requiring surfactant therapy.

Where it's running

• Qumc
  Buraidah, Saudi Arabia Recruiting

Study contacts

• Study coordinator: Shaaban A Elwan, professor of ophthalmology
• Email: shaabanhamid29@gmail.com
• Phone: 00966509507738

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of Skin-to-Skin Care on Premature Infants

  This study tests if regular skin-to-skin care for premature babies can help them get more of their mother's milk and reduce health problems before they go home from the hospital.

  Recruiting Baskent University Ankara Hospital · Ankara · NCT06672913

• Collecting data on the use of Aflibercept in preterm babies with eye condition

  This study is looking at how well Aflibercept works for treating eye problems in preterm babies with retinopathy of prematurity by collecting information from hospitals across the UK.

  Recruiting Bayer · Many Locations · NCT06315556

• Using intranasal dexmedetomidine to manage pain during eye exams in premature infants

  This study tests if a nasal spray of dexmedetomidine can help reduce pain for premature infants during eye exams.

  Recruiting Phase 3 Assaf-Harofeh Medical Center · Be’er Ya‘aqov, Center · NCT06067958

• Imaging the blood vessels in the eyes of premature infants

  This study is testing how blood vessels in the eyes of premature infants grow to better understand retinopathy of prematurity and help prevent childhood blindness.

  Recruiting Duke University · Durham, North Carolina and 1 other locations · NCT05558059

• Assessing retinal health in preterm infants with advanced imaging techniques

  This study is testing a new imaging technique to see if it can better spot eye problems in very preterm infants at risk for vision issues compared to regular photos.

  Recruiting Duke University · Durham, North Carolina and 1 other locations · NCT04995341

• Registry for infants with Retinopathy of Prematurity in Europe

  This study is collecting information about infants with Retinopathy of Prematurity across Europe to better understand how the condition varies and how it's treated.

  Recruiting at 58 sites University Medicine Greifswald · Salzburg and 58 other locations · NCT04939571

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.